Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats

被引:0
|
作者
Huijuan He
Qi Shen
Jian Li
机构
[1] Shanghai Jiao Tong University,School of Pharmacy
来源
Archives of Pharmacal Research | 2011年 / 34卷
关键词
P-glycoprotein; Colchicine; Rhodamine123; Borneol; Intestinal absorption; Bioavailability;
D O I
暂无
中图分类号
学科分类号
摘要
As the most prevalent route of delivery, oral administration has the challenge of potentially low bioavailability in part because P-glycoprotein (P-gp) in the intestinal tract affects absorption. Therefore, absorption enhancers or P-gp inhibitors are strategies to solve this problem. The aim of the present study was to investigate the effects of borneol on transportation of colchicine and rhodamine123, two P-gp substrates, in rats. In vitro transportation was assessed with a diffusion chamber system with isolated rat intestines. Different concentrations of borneol (10, 40 and 80 μg/mL) were prepared in solutions with two P-gp substrates compared with blank solutions. The in vivo effects on colchicine were assessed by a pharmacokinetic study. Borneol enhanced the absorptive transport of two P-gp substrates, which was relevant to the concentration. A pharmacokinetic study showed that in the presence of borneol, a significant increase in Cmax and AUC0→8 of colchicine occurred when compared to colchicine alone. The study showed that borneol affected two P-gp substrates in the intestine, possibly by inhibiting the effects of P-gp and enhancing intestinal absorption of drugs. Therefore, borneol could be developed as a P-gp inhibitor and absorptive enhancer.
引用
收藏
页码:1161 / 1170
页数:9
相关论文
共 50 条
  • [41] ( plus /-)-Borneol Reverses Mitoxantrone Resistance against P-Glycoprotein
    Yang, Rong
    Chen, Zhenxing
    Xie, Fuda
    Xie, Mingxiang
    Liu, Na
    Su, Ziren
    Gu, Jiangyong
    Zhao, Ruizhi
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2021, 61 (01) : 252 - 262
  • [42] Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies
    Shen, Q
    Lin, YL
    Handa, T
    Doi, M
    Sugie, M
    Wakayama, K
    Okada, N
    Fujita, T
    Yamamoto, A
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 313 (1-2) : 49 - 56
  • [43] Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors
    Gherbovet, Olga
    Alvarez, Maria Concepcion Garcia
    Bignon, Jerome
    Roussi, Fanny
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (23) : 10774 - 10780
  • [44] The Effects of PLGA Microparticles on Intestinal Absorption of P-glycoprotein Substrate Using the Everted Rat Intestinal Sac Model
    Derakhshandeh, Katayoun
    Hosseinalizadeh, Aidin
    Nikmohammadi, Maryam
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (11) : 1989 - 1997
  • [45] The effects of PLGA microparticles on intestinal absorption of p-glycoprotein substrate using the everted rat intestinal sac model
    Katayoun Derakhshandeh
    Aidin Hosseinalizadeh
    Maryam Nikmohammadi
    Archives of Pharmacal Research, 2011, 34 : 1989 - 1997
  • [46] Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport
    Sharom, FJ
    Yu, XH
    Didiodato, G
    Chu, JWK
    BIOCHEMICAL JOURNAL, 1996, 320 : 421 - 428
  • [47] Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
    Terao, T
    Hisanaga, E
    Sai, Y
    Tamai, I
    Tsuji, A
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (10) : 1083 - 1089
  • [48] Transport proteins and intestinal metabolism - P-glycoprotein and cytochrome P4503A
    Christians, U
    THERAPEUTIC DRUG MONITORING, 2004, 26 (02) : 104 - 106
  • [49] COUNTERACTING INTERPLAY OF P-GLYCOPROTEIN AND OATP ON INTESTINAL ABSORPTION OF β-BLOCKER TALINOLOL
    Shirasaka, Yoshiyuki
    Shibue, Yuta
    Kuraoka, Erika
    Li, Yan
    Langguth, Peter
    Tamai, Ikumi
    DRUG METABOLISM REVIEWS, 2008, 40 : 214 - 214
  • [50] Role of P-glycoprotein in the intestinal absorption of morphine, fentanyl and methadone.
    Kharasch, ED
    Whittington, D
    Hoffer, CJ
    Altuntas, TG
    Sheffels, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P58 - P58